MedDataX Logo

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

NCT ID: NCT03364920

Last Updated: 2017-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatitis, Acute

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Maresin-1 SAP IPN MODS Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normal level of serum maresin-1

No interventions assigned to this group

abnormal level of serum maresin-1

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Severe Acute Pancreatitis
* Biliary pancreatitis
* 7 days of the onset

Exclusion Criteria

* Surgical patients
* Serious diseases and infection
* Alcoholic pancreatitis
* Hypertriglyceridemia pancreatitis
* Disorder of Glucolipide Metabolism：diabetes mellitus, hypertriglyceridemia, BMI\>30
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Weiqin Li

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Weiqin Li

Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weiqin Li

Role: CONTACT

Phone: 13962531994

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMPSSAP

Identifier Type: -

Identifier Source: org_study_id